U.S. patent application number 17/365630 was filed with the patent office on 2022-04-21 for preparation for attaching to teeth or surrounding part of teeth.
This patent application is currently assigned to LG Household & Health Care Ltd.. The applicant listed for this patent is LG Household & Health Care Ltd.. Invention is credited to Jae-Hyun Ahn, Ji-Young Kim, Jong-Hoon Kim, In-Ho Lee, Sang-Min Lee.
Application Number | 20220117856 17/365630 |
Document ID | / |
Family ID | |
Filed Date | 2022-04-21 |
![](/patent/app/20220117856/US20220117856A1-20220421-D00000.png)
![](/patent/app/20220117856/US20220117856A1-20220421-D00001.png)
![](/patent/app/20220117856/US20220117856A1-20220421-D00002.png)
![](/patent/app/20220117856/US20220117856A1-20220421-D00003.png)
![](/patent/app/20220117856/US20220117856A1-20220421-D00004.png)
United States Patent
Application |
20220117856 |
Kind Code |
A1 |
Kim; Ji-Young ; et
al. |
April 21, 2022 |
Preparation for Attaching to Teeth or Surrounding Part of Teeth
Abstract
The present invention provides a preparation for attaching to
teeth or tooth peripheries, which comprises a malleable oral
composition and an active ingredient for intra-oral delivery.
Further, the present invention provides a preparation for attaching
to teeth or tooth peripheries, which comprises an oral composition
in a hardening ointment-phase and an active ingredient for
intra-oral delivery. The preparation of the present invention may
give high adhesive force to the desired site in spite of gaps
between teeth or curves of teeth. The preparation of the present
invention having high adhesive force increases the time of adhesion
to a target site in the oral cavity, and thus may be advantageous
in achieving an intended effect.
Inventors: |
Kim; Ji-Young; (Daejeon,
KR) ; Ahn; Jae-Hyun; (Daejeon, KR) ; Kim;
Jong-Hoon; (Daejeon, KR) ; Lee; In-Ho;
(Daejeon, KR) ; Lee; Sang-Min; (Daejeon,
KR) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
LG Household & Health Care Ltd. |
Seoul |
|
KR |
|
|
Assignee: |
LG Household & Health Care
Ltd.
Seoul
KR
|
Appl. No.: |
17/365630 |
Filed: |
July 1, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15778127 |
May 22, 2018 |
11083671 |
|
|
PCT/KR2016/012934 |
Nov 10, 2016 |
|
|
|
17365630 |
|
|
|
|
International
Class: |
A61K 8/02 20060101
A61K008/02; A61K 8/25 20060101 A61K008/25; A61Q 11/00 20060101
A61Q011/00; A61K 8/69 20060101 A61K008/69; A61K 8/19 20060101
A61K008/19; A61K 8/81 20060101 A61K008/81; A61K 9/06 20060101
A61K009/06; A61K 8/73 20060101 A61K008/73; A61K 47/02 20060101
A61K047/02; A61K 47/36 20060101 A61K047/36; A61K 47/12 20060101
A61K047/12; A61K 9/00 20060101 A61K009/00; A61K 9/70 20060101
A61K009/70 |
Foreign Application Data
Date |
Code |
Application Number |
Nov 24, 2015 |
KR |
10-2015-0164928 |
Dec 3, 2015 |
KR |
10-2015-0171541 |
Claims
1. A preparation for attaching to teeth or tooth peripheries, which
comprises: an oral composition in a hardening ointment-phase; and
an active ingredient for intra-oral delivery, wherein the oral
composition in the hardening ointment-phase comprises a phase
transition material, a phase transition auxiliary material, and an
attachment-enhancing material of a phase transition composition,
wherein the phase transition material includes carrageenan, pectin,
xyloglucan, gellan gum, ammonium alginate, magnesium alginate,
potassium alginate, sodium alginate, lithium alginate, chitosan,
poly-lactic acid (poly(D,L-lactic acid)), polylactide-co-glycolide
(poly(DL-lactide-co-glycolide)), poly-caprolactone, polyacrylic
acid (carbopol), polyvinylacetal diethyl aminoacetate (AEA),
hydroxypropylmethyl cellulose, poly(methacrylic acid)-poly(ethylene
glycol), poly(D,L-lactide)-block-poly(ethylene
glycol)-block-poly(D,L-lactide), PEG-oligoglycolyl-acrylate,
poly(N-isopropyl acrylamide), sucrose acetate isobutyrate,
polyvinyl alcohol, glyceryl monooleate, glyceryl monolinoleate,
glyceryl monoarachidonate, glyceryl monostearate, or a mixture
thereof, wherein the phase transition auxiliary material includes a
calcium ion source of calcium sulfate, calcium carbonate, calcium
phosphate dibasic (CaHPO.sub.4), barium carbonate, zinc carbonate,
calcium chloride, calcium lactate, calcium citrate, calcium
aspartate, calcium saccharate, calcium oxovalerate, calcium
gluconate, calcium lactobionate or calcium lactogluconate; a
chelating agent of barium carbonate, zinc carbonate, sodium
bicarbonate, sodium carbonate, tetraborate or tripolyphosphate;
acetic acid, malic acid, lactic acid, gluconic acid, ascorbic acid,
boric acid or a mixture or a salt thereof; or NaOH, KOH or a
mixture thereof, wherein the attachment-enhancing material of the
phase transition composition includes precipitated silica for
thickening, colloidal silicone dioxide, polyvinyl pyrrolidone, poly
methyl vinyl ether and maleic acid copolymer, shellac, rosin,
poloxamer, hyaluronic acid, acrylate copolymer, hydroxypropyl
methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), polyacrylic
acid, polyethylene glycol, ethyl cellulose or a mixture thereof, or
a crosslinked body thereof, wherein the active ingredient is sodium
fluoride, stannous fluoride, indium fluoride, amine fluoride,
sodium monofluorophosphate, tetrasodium pyrophosphate (TSPP),
sodium acid pyrophosphate (SAPP), sodium tripolyphosphate (STP),
sodium potassium pyrophosphate, tetrapotassium pyrophosphate,
acidic sodium metaphosphate, acidic sodium polyphosphate,
triclosan, chlorhexidine, alexidine, hexetidine, sanguinarine,
benzalkonium chloride, salicylanilide, domiphen bromide,
cetylpyridinium chloride (CPC), tetradecylpyridinium chloride
(TPC), aspirin, ketorolac, flurbiprofen, piroxicam, meclofenamic
acid, thiamine, riboflavin, nicotinic acid, pantothenic acid,
pyridoxine, biotin, folic acid, vitamin B12, lipoic acid, ascorbic
acid, vitamin A, vitamin D, vitamin E, vitamin K, titrated extract
of Zea Mays L. unsaponifiable fraction, Magnoliae Cortex, Myrrha,
Rhatany, Chamomile, policresulen, titrated extract of Centella
Asiatica, nutmeg extract, dexpanthenol, .beta.-sitosterol, acetyl
salicylic acid, zinc chloride, potassium phosphate, potassium
diphosphate, calcium chloride, oxalic acid, potassium oxalate,
ferric oxalate, vitamin E, or a mixture thereof, and wherein the
preparation has the initial hardness of from 0.1 g to 20,000 g,
measured at Compression mode of Texture Analyzer (TA), at the time
of attachment; and has the final hardness of 40,000 g or less,
measured at Compression mode of Texture Analyzer (TA), at the time
of removal.
2. The preparation of claim 1, wherein the active ingredient is
mixed with the oral composition in a hardening ointment-phase and
contained in the preparation.
3. The preparation of claim 1, wherein the preparation becomes
hardened and substantially loses its moldability in 5 minutes to 3
hours after the preparation is attached to teeth or tooth
peripheries under the humidity and temperature conditions of the
oral cavity.
4. The preparation of claim 3, wherein the becoming hardened and
losing its moldability means that the preparation becomes to have a
viscosity of 5000 cps or higher, which is measured by using
Brookfield viscometer equipped with No. 6, 7 spindles at 20.degree.
C., 5 to 20 rpm, in 5 minutes to 3 hours after the preparation is
attached to teeth or tooth peripheries.
5. The preparation of claim 1, wherein the time of removal is when
the amount of the active ingredient released into the oral cavity
is 60 wt % or more, based on the amount of the active ingredient
contained in the initial preparation, after 30 minutes from the
attachment of the preparation to teeth or tooth peripheries.
6. The preparation of claim 1, wherein the preparation increases
its area when the preparation is pressed by applying force at the
beginning of attachment.
7. The preparation of claim 1, wherein the preparation is
one-formulation type; or two-formulation type consisting of the
first formulation and the second formulation.
8. The preparation of claim 1, wherein the oral composition in a
hardening ointment-phase further comprises a material for helping
drug release, and wherein the material for helping drug release
includes at least one acid and at least one base, and wherein the
preparation is a two-formulation type consisting of a first
formulation containing the at least acid and a second formulation
containing the at least one base.
9. The preparation of claim 1, wherein water-solubility of the
preparation, measured at 32.degree. C., 1 atm after 5 minutes to 3
hours from attachment of the preparation to teeth or tooth
peripheries, is 20 wt % or less.
10. The preparation of claim 1, wherein the preparation further
comprises a backing layer.
11. A preparation for attaching to teeth or tooth peripheries,
which comprises: a malleable oral composition; and an active
ingredient for intra-oral delivery, wherein the malleable oral
composition comprises a phase transition material, a phase
transition auxiliary material, and an attachment-enhancing material
of a phase transition composition, wherein the phase transition
material includes carrageenan, pectin, xyloglucan, gellan gum,
ammonium alginate, magnesium alginate, potassium alginate, sodium
alginate, lithium alginate, chitosan, poly-lactic acid
(poly(D,L-lactic acid)), polylactide-co-glycolide
(poly(DL-lactide-co-glycolide)), poly-caprolactone, polyacrylic
acid (carbopol), polyvinylacetal diethyl aminoacetate (AEA),
hydroxypropylmethyl cellulose, poly(methacrylic acid)-poly(ethylene
glycol), poly(D,L-lactide)-block-poly(ethylene
glycol)-block-poly(D,L-lactide), PEG-oligoglycolyl-acrylate,
poly(N-isopropyl acrylamide), sucrose acetate isobutyrate,
polyvinyl alcohol, glyceryl monooleate, glyceryl monolinoleate,
glyceryl monoarachidonate, glyceryl monostearate, or a mixture
thereof, wherein the phase transition auxiliary material includes a
calcium ion source of calcium sulfate, calcium carbonate, calcium
phosphate dibasic (CaHPO.sub.4), barium carbonate, zinc carbonate,
calcium chloride, calcium lactate, calcium citrate, calcium
aspartate, calcium saccharate, calcium oxovalerate, calcium
gluconate, calcium lactobionate or calcium lactogluconate; a
chelating agent of barium carbonate, zinc carbonate, sodium
bicarbonate, sodium carbonate, tetraborate or tripolyphosphate;
acetic acid, malic acid, lactic acid, gluconic acid, ascorbic acid,
boric acid or a mixture or a salt thereof; or NaOH, KOH or a
mixture thereof, wherein the attachment-enhancing material of the
phase transition composition includes precipitated silica for
thickening, colloidal silicone dioxide, polyvinyl pyrrolidone, poly
methyl vinyl ether and maleic acid copolymer, shellac, rosin,
poloxamer, hyaluronic acid, acrylate copolymer, hydroxypropyl
methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), polyacrylic
acid, polyethylene glycol, ethyl cellulose or a mixture thereof, or
a crosslinked body thereof, wherein the active ingredient is sodium
fluoride, stannous fluoride, indium fluoride, amine fluoride,
sodium monofluorophosphate, tetrasodium pyrophosphate (TSPP),
sodium acid pyrophosphate (SAPP), sodium tripolyphosphate (STP),
sodium potassium pyrophosphate, tetrapotassium pyrophosphate,
acidic sodium metaphosphate, acidic sodium polyphosphate,
triclosan, chlorhexidine, alexidine, hexetidine, sanguinarine,
benzalkonium chloride, salicylanilide, domiphen bromide,
cetylpyridinium chloride (CPC), tetradecylpyridinium chloride
(TPC), aspirin, ketorolac, flurbiprofen, piroxicam, meclofenamic
acid, thiamine, riboflavin, nicotinic acid, pantothenic acid,
pyridoxine, biotin, folic acid, vitamin B12, lipoic acid, ascorbic
acid, vitamin A, vitamin D, vitamin E, vitamin K, titrated extract
of Zea Mays L. unsaponifiable fraction, Magnoliae Cortex, Myrrha,
Rhatany, Chamomile, policresulen, titrated extract of Centella
Asiatica, nutmeg extract, dexpanthenol, .beta.-sitosterol, acetyl
salicylic acid, zinc chloride, potassium phosphate, potassium
diphosphate, calcium chloride, oxalic acid, potassium oxalate,
ferric oxalate, vitamin E, or a mixture thereof, and wherein the
preparation has the initial compressibility of 0.1 to 30,000 gs,
measured at Compression mode of Texture Analyzer (TA); and has the
final compressibility of 50,000 gs or less, measured at Compression
mode of Texture Analyzer (TA).
12. The preparation of claim 11, wherein the active ingredient is
mixed with the malleable oral composition and dispersed in the
preparation.
13. The preparation of claim 11, wherein the time of removal is
when the amount of the active ingredient released into the oral
cavity is 60 wt % or more, based on the amount of the active
ingredient contained in the initial preparation, after 30 minutes
from the attachment of the preparation to teeth or tooth
peripheries.
14. The preparation of claim 11, wherein the preparation increases
its area when the preparation is pressed by applying force at the
beginning of attachment.
15. The preparation of claim 11, wherein the malleable oral
composition further comprises a material for helping drug release,
and wherein the material for helping drug release includes at least
one acid and at least one base, and wherein the preparation is a
two-formulation type consisting of a first formulation containing
the at least acid and a second formulation containing the at least
one base.
16. The preparation of claim 11, wherein the preparation is
one-formulation type; or two-formulation type consisting of the
first formulation and the second formulation.
17. The preparation of claim 11, wherein the preparation becomes
hardened and substantially loses its moldability in 5 minutes to 3
hours after the preparation is attached to teeth or tooth
peripheries under the humidity and temperature conditions of the
oral cavity.
18. The preparation of claim 17, wherein the becoming hardened and
losing its moldability means that the preparation becomes to have a
viscosity of 5000 cps or higher, which is measured by using
Brookfield viscometer equipped with No. 6, 7 spindles at 20.degree.
C., 5 to 20 rpm, in 5 minutes to 3 hours after the preparation is
attached to teeth or tooth peripheries.
19. The preparation of claim 11, wherein water-solubility of the
preparation, measured at 32.degree. C., 1 atm after 5 minutes to 3
hours from attachment of the preparation to teeth or tooth
peripheries, is 20 wt % or less.
20. The preparation of claim 11, wherein the preparation further
comprises a backing layer.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 15/778,127 filed on May 22, 2018, which is a national phase
entry under 35 U.S.C. .sctn. 371 of International Application No.
PCT/KR2016/012934, filed Nov. 10, 2016, which claims priority to
Korean Patent Application No. 10-2015-0164928, filed Nov. 24, 2015,
and Korean Patent Application No. 10-2015-0171541, filed Dec. 3,
2015, the disclosures of which are incorporated herein by
reference.
TECHNICAL FIELD
[0002] The present invention relates to a preparation for
delivering a drug into the oral cavity, and more specifically, it
relates to a novel form of an oral preparation, which can
effectively deliver an active ingredient to the desired site in the
oral cavity.
BACKGROUND OF THE INVENTION
[0003] In order to deliver an oral active ingredient into the oral
cavity, the contact time with an active ingredient and the delivery
amount play an important role.
[0004] Paste formulations such as toothpaste have a disadvantage
that it is difficult to provide sufficient contact time at the
target site due to insufficient viscosity and high solubility, and
mouth trays intended for intraoral drug delivery have a
disadvantage that they have a strong sense of foreign body and
difficult to deliver a drug locally due to their shape
characteristics. Patch type or strip type is thin, so it is
difficult to deliver sufficient amount of an active ingredient, and
flexibility is low, so there is a disadvantage that it is difficult
to be adhered to gaps between teeth, boundary area between gums and
teeth, and the like.
[0005] In order to solve the adhesion problem to the gaps between
teeth, boundary area between gums and teeth and the like, Korean
Patent No. 10-0623859 developed a delivery system for a tooth
whitening component using in situ gelling, but there was a
disadvantage that it is necessary to use a separate backing layer
because it is highly flowable when applied to the tooth surface.
Further, WO 2003/037276 discloses a preparation to be sprayed in
the oral cavity due to its low initial viscosity, but there was a
problem that the difference between the normal storage temperature
(especially in summer) and the temperature in the oral cavity is
small and it is difficult to remove it because the phase transition
does not occur rapidly unless it is applied very thin.
[0006] U.S. Pat. No. 5,989,569 discloses about applying a drug to
the surface of a strip and delivering the drug by pressure, but
there were problems that the active ingredient is temporarily
released because the drug is applied on the surface of the strip
and adhered to teeth as it is, and it may cause strong stimulus in
the gums around the teeth. Further, there was a disadvantage that
physical properties, in particular, flexibility, of the drug to be
applied are different from those of the strip, and therefore,
adhesion to gaps between teeth is difficult.
[0007] The inventors of the present invention have studied for a
long time to develop a novel form of a preparation, which can
effectively deliver a drug into the oral cavity with convenience of
use, thereby completing the present invention.
SUMMARY OF THE INVENTION
[0008] In order to solve the above problems, the present invention
provides a preparation for delivering an active ingredient whose
physical properties are changed before attachment to teeth and
after a period of time after the attachment.
[0009] Further, the present invention provides a preparation in a
form that can be freely changed before use, and can be adhered well
to gaps between teeth or a boundary area between gums and
teeth.
[0010] Further, the present invention provides a novel form of an
oral preparation having excellent feeling of use, which can be
conveniently used without any feeling of being stained or sticky in
the hands when attached to teeth or tooth peripheries.
[0011] These and other objects and advantages of the present
invention may be understood from the following detailed description
and will become more fully apparent from the exemplary embodiments
of the present invention. Also, it will be easily understood that
the objects and advantages of the present invention may be realized
by the means shown in the appended claims and combinations
thereof.
Definition
[0012] The term `tooth peripheries` used herein is generally a
concept involving a region represented by gums, and may be used to
mean including all of the mucosal regions around teeth. The tooth
peripheries can be used to mean covering the region where an active
ingredient for intra-oral delivery can be delivered together with
the teeth when the preparation is applied to the teeth in the
structure of the preparation. Herein, `teeth or tooth peripheries`
is used together with `teeth`, and it may be understood herein to
include both the teeth and the tooth peripheries even if it is
described only as `teeth`.
[0013] The term `oral composition in a hardening ointment-phase`
used herein means an oral composition that does not have a certain
shape before adhered to teeth, has an ointment phase of free-shape
transformation, gradually loses its fluidity, and its shape is
fixed. Namely, it means an ointment-type oral composition, which
has a characteristic that the preparation of the present invention
is ointment type when the preparation is applied to teeth or tooth
peripheries, after application, its viscosity increases up to the
point of adhesion, and it hardens at the point when it is removed
from teeth after adhesion.
[0014] The `hardening ointment-phase` preparation may mean a
preparation that is a semi-solid-type ointment such as dough or
clay after application, but is molded with external force such as
heat or pressure over time, gradually loses its moldability and
hardens, and finally permanently transformed.
[0015] The term `hardening` used herein may include not only
hardening by the formation of a network structure such as an ionic
crosslinked structure like an egg-box model but also a decrease in
fluidity accompanied by a progress of polymerization reaction by
light or a catalyst, and may mean a state of hardly hardening due
to various factors such as degree of absorption of water and degree
of exposure to air, and no further shape transformation.
[0016] The term `malleability` used herein may mean that the
preparation of the present invention has shape transformability or
can have moldability by external pressure. It also mean that the
preparation is sufficiently flexible and it is possible to
transform to such a degree that when the preparation is adhered in
the mouth, it can be completely adhered to gaps between teeth or
the fine portion between teeth and gums.
[0017] Herein, not only the case that the preparation is stretched
to the left and right but also the case that when it is placed on a
flat surface and pressed with a certain force, the preparation is
transformed by stretching in all directions can be included in the
range of malleability. Further, any form causing change in
appearance can be included in the range of malleability. With
malleability, an object can be compressed or the area can be
widened in a certain hardness range.
[0018] The term `hardness` used herein may mean the amount of force
required to compress the preparation. Hardness of the preparation
of the present invention is measured at compression test mode of
Stable Micro System TA XT Plus. After filling 20 g of the
preparation into a 50 mL beaker, a 20 mm diameter aluminum probe
for hardness measurement is set, and then hardness is measured with
test speed of 1.5 mm/s, distance as target mode and distance of 10
mm. Hardness is understood as the peak value of the first cycle
calculated. The unit can be expressed as g (g force).
[0019] The term `compressibility` used herein may mean the force
applied until just before the preparation is broken, cut or
destroyed while it is compressed. Compressibility of the
preparation of the present invention is measured at compression
test mode of Stable Micro System TA XT Plus. After filling 20 g of
the preparation into a 50 mL beaker, a 20 mm diameter aluminum
probe for compressibility measurement is set, and then
compressibility is measured with test speed of 1.5 mm/s, distance
as target mode and distance of 10 mm. Compressibility is understood
as the area value of the first cycle calculated. The unit can be
expressed as gs (g force*sec).
[0020] The term `compressibility` used herein may mean a
characteristic that when compressing the preparation, it can expand
without breaking or cutting while its volume is reduced.
[0021] The term `elongation percentage` used herein means the
degree to which the preparation can be stretched in all directions
when load is applied, such as when a preparation is compressed
between rollers. The term `elongation percentage` used herein can
be understood to mean "plane strain" unless otherwise specified.
Good elongation percentage can be understood as having
malleability.
[0022] Meaning of the term `applied to teeth` used herein may
include from immediately after application of the preparation to
teeth to before the preparation adhered to teeth after a user
applies pressure to the preparation. In the case of two-formulation
type, the term `after applying the preparation` in the present
invention may mean after applying the mixture of the first
formulation and the second formulation to teeth.
[0023] The term `when adhering the preparation to teeth` in the
present invention means the time of adhering the preparation to
curves of teeth, gaps between teeth, or between teeth or gums by
applying pressure after a certain period of time after application
of the preparation to teeth, and preferably, the adhesion may be
understood to be about 10 min or less, preferably about 5 min or
less, more preferably about 1 to 3 min or less after applying the
preparation of the present invention to teeth.
[0024] The term `time of removal of the preparation` in the present
invention may mean the time that the drug is released from the oral
cavity after it is adhered to teeth or a surrounding tissue of
teeth and then the preparation is removed therefrom. Depending on
the purpose and use of the preparation, and the release amount of
the drug, but it may be removed after 2 hr from attachment, but it
may be removed within 30 min, more preferably within 10 min after
adhered to teeth in view of convenience of use. Hardness of the
preparation at the time of removal may be equal to the time at
which the preparation is applied to teeth and the time at which the
preparation is adhered to teeth, and hardness of the preparation at
the time of removal may be increased.
[0025] The term `preparation` used herein means to a product made
by processing the active ingredient to ensure its therapeutic
effect without affecting effectiveness of the active
ingredient.
DETAILED DESCRIPTION OF THE INVENTION
[0026] The present invention provides a preparation for attaching
to teeth or tooth peripheries, which comprises an oral composition
in a hardening ointment-phase, and an active ingredient for
intra-oral delivery. The present inventors have studied on a drug
delivery system capable of delivering an active ingredient into the
oral cavity, thereby suggesting a novel form of a drug delivery
system and a novel method for delivering the active ingredient into
the oral cavity using such a system.
[0027] The present inventors have studied for a long time on a
novel drug delivery system capable of effectively delivering an
active ingredient to specific sites in the oral cavity (for
example, sites requiring tooth whitening, sites of oral
inflammation, sites of periodontal disease, etc.). As a result, a
novel form of an oral preparation, which can be conveniently
applied to teeth or a mucosal region in the oral cavity, and can be
adhered well to a curvy region and gaps between teeth so as to
increase the drug reach rate at the desired site, has been
developed.
[0028] One embodiment of the present invention provides a
preparation for attaching to teeth or tooth peripheries, wherein an
oral composition in a hardening ointment-phase and an active
ingredient for intra-oral delivery are mixed. For example, the
active ingredient can be homogeneously dispersed in the oral
composition, and the case that the ingredient is inhomogeneously
dispersed is also included in the mixing of the present
invention.
[0029] According to one embodiment of the present invention,
preparation of the present invention may substantially lose
moldability at the time of the final removal, and preferably, at
the time of the final removal, viscosity may be 5,000 cps or higher
and moldability may be lost. The preparation may have viscosity of
5000 cPs or higher, preferably 10,000 cPs or higher, more
preferably 200,000 cPs or higher, which is measured by using
Brookfield viscometer equipped with No. 6, 7 spindles at a
temperature of 20.degree. C. (room temperature), 5 to 20 rpm, at
the time of removal of the preparation after the preparation is
applied to teeth or tooth peripheries and then the drug is
released. Viscosity at the time of the final removal of the
preparation may vary depending on the type and amount of a phase
transition material, a phase transition auxiliary material, a
material for helping attachment of the phase transition material
and the like, contained in the preparation, and preferably,
viscosity measured at the time of removal may be 5,000 cPs or
higher and 104,000,000 cPs or less.
[0030] According to one embodiment of the present invention, the
viscosity of the preparation attached to teeth, measured at the
time of removal, may be increased two folds or more, preferably
three folds or more, more preferably five folds or more, compared
to the viscosity measured at the time of application of the
preparation to teeth or tooth peripheries.
[0031] According to another embodiment of the present invention,
the viscosity of the preparation of the present invention, measured
at the time of removal, may be 5,000 cPs or higher, and may have a
value two folds or more than the viscosity measured at the time of
application to teeth.
[0032] The oral composition in a hardening ointment-phase contained
in the preparation of the present invention may comprise a phase
transition material, a phase transition auxiliary material, an
attachment-enhancing material of the phase transition composition,
and a material for helping drug release.
[0033] The phase transition material is a substance that causes
hardening of the oral composition in a hardening ointment-phase. It
may be carrageenan, pectin, xyloglucan, gellan gum, ammonium
alginate, magnesium alginate, potassium alginate, sodium alginate,
lithium alginate, chitosan, poly-lactic acid (poly(D,L-lactic
acid)), polylactide-co-glycolide (poly(DL-lactide-co-glycolide)),
poly-caprolactone, polyacrylic acid (carbopol), polyvinylacetal
diethyl aminoacetate (AEA), hydroxypropylmethyl cellulose,
poly(methacrylic acid)-poly(ethylene glycol),
poly(D,L-lactide)-block-poly(ethylene
glycol)-block-poly(D,L-lactide), PEG-oligoglycolyl-acrylate,
poly(N-isopropyl acrylamide), sucrose acetate isobutyrate,
polyvinyl alcohol, glyceryl monooleate, glyceryl monolinoleate,
glyceryl monoarachidonate, glyceryl monostearate and the like alone
or a combination of two or more thereof. Any material that can be
used as a phase transition material in the art can be used and is
not limited to the above examples.
[0034] The hardening ointment-phase composition may comprise the
attachment-enhancing material of the phase transition composition,
that is adhesive to teeth or has adhesiveness retention force; and
that is well compatible with the phase transition material. For
example, the material may be precipitated silica for thickening,
colloidal silicone dioxide, polyvinyl pyrrolidone, poly methyl
vinyl ether and maleic acid copolymers (gantrez), shellac, rosin,
poloxamer, hyaluronic acid, acrylate copolymer (Eudragit L-100,
L-100,55), hydroxypropyl methyl cellulose (HPMC), hydroxypropyl
cellulose (HPC), polyacrylic acid, polyethylene glycol, ethyl
cellulose or a mixture thereof, but not limited thereto.
Preferably, it may be hydroxypropyl methyl cellulose (HPMC) or
ethyl cellulose or a mixture thereof. Such polymer can be used by
dissolving thereof in water or a solvent (for example, ethanol),
but crosslinked polymers also can be used. For example, the polymer
may be crosslinked polyacrylic acid, or crosslinked polyvinyl
pyrrolidone, and such crosslinked polymer can be used alone or in
combination with a non-crosslinked polymer. In the case of a
polymer obtained by cross-linking polymers having excellent
adhesive force to teeth or gums, it is advantageous to improve
adhesion of the composition as well as to improve the residuality
because it is not dissolved in water or ethanol while exhibiting
adhesive force after absorbing water.
[0035] The phase transition auxiliary material is a substance that
can induce phase transition, control phase transition rate and
adjust a degree of phase transition, and a calcium ion can be used.
It is preferable that the calcium ion is water-soluble, but a
calcium ion, which is insoluble in neutral or alkaline condition
but can easily be converted into water-soluble in an acidic
condition, also can be used. For example, the phase transition
auxiliary material may be at least one selected from: a calcium ion
source of calcium carbonate, calcium phosphate dibasic
(CaHPO.sub.4), barium carbonate, zinc carbonate, calcium chloride,
calcium lactate, calcium citrate, calcium aspartate, calcium
saccharate, calcium oxovalerate, calcium gluconate, calcium
lactobionate and calcium lactogluconate; a chelating agent such as
barium carbonate, zinc carbonate, sodium bicarbonate, sodium
carbonate, tetraborate, tripolyphosphate, ethylenediamine
tetraacetic acid, tetrasodium pyrophosphate, sodium acid
pyrophosphate, Sporix (acidic sodium metaphosphate) and the like;
acetic acid, malic acid, lactic acid, gluconic acid, ascorbic acid
or a mixture thereof, or a salt thereof; and NaOH, KOH or a mixture
thereof.
[0036] The phase transition material, the phase transition
auxiliary material and the attachment-enhancing material of the
phase transition material contained in the hardening ointment-phase
composition are exemplarily listed, but not necessarily limited the
above examples. According to another embodiment of the present
invention, depending on the mechanism, the phase transition
material, the phase transition auxiliary material and the
attachment-enhancing material can be used indiscriminately. For
example, if the phase transition material is polyvinyl alcohol, the
phase transition auxiliary material may be tetraborate, and the
material for enhancing adhesive force may be alginate or colloidal
silica. In another embodiment, if the phase transition material is
alginate, the phase transition auxiliary material may be calcium,
and the material for enhancing adhesive force may be methyl vinyl
ether and maleic acid copolymer (gantrez).
[0037] The material for helping drug release may be any material
that can form a channel, a porous structure or bubble (foam) in the
formulation. For example, in the case that the preparation is
consisting of two formulations of the first formulation and the
second formulation, one formulation contains an acid and the other
contains a base, so that bubbles are formed in the formulation when
the two formulations meet to form a hardening ointment-phase.
Namely, the first formulation contains acetic, lactic, malic,
gluconic, ascorbic acids and the like or a water-soluble salt
thereof, e.g., sodium citrate, and the second formulation contains
any base selected from the group consisting of sodium hydroxide
(NaOH), potassium hydroxide (KOH), sodium bicarbonate (baking soda)
and sodium carbonate. Preferably, the acid may be acetic acid, and
the base may be sodium carbonate, and more preferably, those may be
sodium citrate and sodium bicarbonate, which are an acid and a base
mainly used in a toothpaste.
[0038] The active ingredient may include, for example, ingredients
that can improve oral symptoms, and for example, it may be an
ingredient for tooth whitening, an ingredient for preventing cavity
containing a fluoride ion source, an ingredient for inhibiting
tartar formation, an anti-inflammatory ingredient, an
anti-bacterial ingredient, other vitamins, mineral ingredients and
the like. Further, it may also include ingredients for improving
sensitive teeth and for relieving its symptoms, and the like. More
specifically, for example, it may include: at least one fluoride
ion source selected from the group consisting of sodium fluoride,
stannous fluoride, indium fluoride, amine fluoride and sodium
monofluorophosphate; a reminerlaization agent containing
hydroxyapatite; and an ingredient for tooth whitening selected from
hydrogen peroxide, carbamide peroxide, calcium peroxide, perborate,
percarbonate, peroxyacid, persulfate, calcium chloride, barium
chloride, magnesium chloride, lithium chloride, sodium chloride or
a mixture thereof. For enhancing whitening effect, a condensed
phosphate can be used together with peroxides. The condensed
phosphate, which can be used, may be at least one of tetrasodium
pyrophosphate (TSPP), sodium acid pyrophosphate (SAPP), sodium
tripolyphosphate (STP), sodium potassium pyrophosphate,
tetrapotassium pyrophosphate, acidic sodium metaphosphate and
acidic sodium polyphosphate, and it may be used together with
peroxides. Such condensed phosphate also can be used for removing
tartar or inhibiting tartar formation. Further, it can also
contribute to the improvement of whitening effect by removing the
metal which affects the stain formation of teeth as a chelating
agent. The active ingredient may include an anti-bacterial agent
including triclosan, chlorhexidine, alexidine, hexetidine,
sanguinarine, benzalkonium chloride, salicylanilide, domiphen
bromide, cetylpyridinium chloride (CPC), tetradecylpyridinium
chloride (TPC) or a mixture thereof; an anti-inflammatory agent
including aspirin, ketorolac, flurbiprofen, piroxicam, meclofenamic
acid or a mixture thereof; thiamine, riboflavin, nicotinic acid,
pantothenic acid, pyridoxine, biotin, folic acid, vitamin B12,
lipoic acid, ascorbic acid, vitamin A, vitamin D, vitamin E,
vitamin K or a mixture thereof; or a mixture thereof, but not
limited thereto. Further, the drug effective for preventing and
improving periodontal diseases may be titrated extract of Zea Mays
L. unsaponifiable fraction, Magnoliae Cortex, Myrrha, Rhatany,
Chamomile, policresulen, titrated extract of Centella Asiatica,
nutmeg extract, dexpanthenol, .beta.-sitosterol, acetyl salicylic
acid and the like alone, or a mixture thereof of a certain mixing
ratio. The ingredient for improving and relieving sensitive teeth
symptoms may be zinc chloride, potassium phosphate, potassium
diphosphate, calcium chloride, oxalic acid, potassium oxalate,
ferric oxalate, vitamin E and the like alone, or a combination of
two or more thereof.
[0039] According to one embodiment of the present invention, the
preparation may be one-formulation type, or two-formulation type
consisting of the first formulation and the second formulation, and
three or more formulations may be mixed as required.
[0040] The first formulation and the second formulation of the
two-formulation type preparation are mixed and applied to teeth or
tooth peripheries, and in order to apply the preparation to teeth
or tooth peripheries, the viscosity of the preparation measured
after mixing the first formulation and the second formulation may
be increased, compared to before mixing. After mixing, it may have
moldability like dough.
[0041] The two-formulation type preparation may contain the active
ingredient in the first formulation, the second formulation or both
of the first formulation and the second formulation.
[0042] The two-formulation type preparation may selectively contain
the phase transition material, the phase transition auxiliary
material and the attachment-enhancing material in the first
formulation, the second formulation or both of the first
formulation and the second formulation.
[0043] For example, the two-formulation type preparation may
contain magnesium alginate as a phase transition material in the
first formulation. The two-formulation type preparation may contain
calcium chloride as a material for helping hardening of the phase
transition material, and hydroxypropyl cellulose as a material for
helping attachment to teeth or tooth peripheries in the second
formulation. In this case, the active ingredient may be
appropriately contained in consideration of compatibility of the
polymers contained in the first formulation and the second
formulation, characteristics thereof and the like.
[0044] The preparation of the present invention may substantially
lose moldability at the time of removal after attachment to teeth.
Preferably, the time of removal may mean at 5 min to 3 hr,
preferably 8 min to 90 min after application to teeth or tooth
peripheries. For example, it may be removed after 10 min, 30 min or
1 hr from attachment.
[0045] In another embodiment, the time of removal after attachment
to teeth may be, for example, the time at which the amount of the
active ingredient contained in the preparation becomes 30 wt % or
less, based on the total loaded weight of the drug at the
beginning.
[0046] The substantially losing moldability means a hardening state
in which the preparation loses physical properties such as dough
and its shape transformation is not possible at the time of removal
of the preparation after application. In one embodiment of the
present invention, water-solubility of the preparation, measured at
32.degree. C., 1 atm at a state of substantially losing
moldability, may be 20 wt % or less, preferably 15 wt % or less,
more preferably 10 wt % or less, and the most preferably 1 wt % to
10 wt %.
[0047] The preparation may further comprise a backing layer as
required when it is attached to teeth or tooth peripheries. The
backing layer may include a water-insoluble polymer, generally used
in an oral film, and for example, polyethylene (PE), polypropylene
(PP), ethylene vinyl acetate (EVA), cellulose acetate phthalate,
shellac, polyvinyl acetate, ethyl cellulose, polymethyl
methacrylate, methacryloylethyl betain/methacrylate copolymer
(Yukaformer; Manufacturer: Mitsubishi), methacrylic acid copolymer
(Eudragit L 100, Eudragit L 12,5, Eudragit L 100-55, Eudragit L
30D-55), aminoalkyl methacrylate copolymer (Eudragit E 100,
Eudragit E 12,5, Eudragit RL 100, Eudragit RL 30D) and the like may
be used.
[0048] The present invention provides a preparation for attaching
to teeth or teeth and gums around teeth, which comprises a
malleable oral composition, and an active ingredient for intra-oral
delivery. The present inventors have studied on a drug delivery
system capable of delivering an active ingredient into the oral
cavity, thereby suggesting a novel form of a drug delivery system
and a novel method for delivering the active ingredient into the
oral cavity using such a system.
[0049] The present inventors have studied for a long time on a
novel drug delivery system capable of effectively delivering an
active ingredient to specific sites in the oral cavity (for
example, sites requiring tooth whitening, sites of oral
inflammation, sites of periodontal disease, etc.). As a result, a
novel form of an oral preparation, which can conveniently be
applied to teeth or a mucosal region in the oral cavity, and can be
adhered well to a curvy region and gaps between teeth so as to
increase the drug reach rate at the desired site, has been
developed.
[0050] One embodiment of the present invention provides a
preparation for attaching to teeth or tooth peripheries, wherein a
malleable oral composition and an active ingredient for intra-oral
delivery are mixed. For example, the active ingredient can be
homogeneously dispersed in the oral composition, and the case that
the ingredient is inhomogeneously dispersed is also included in the
mixing of the present invention.
[0051] According to one embodiment of the present invention, the
preparation of the present invention has semi-solid property at the
same time, so that it can be adhered to curves or gaps.
[0052] The preparation of the present invention may have a form
such as dough or clay, and it can be applied to teeth or tooth
peripheries as the form of an ointment.
[0053] The preparation of the present invention may have the
initial hardness in a range from 0.1 g to 20,000 g, preferably from
10 g to 12,000 g, measured at Compression mode of Texture Analyzer
(TA), at the time of attachment. When the initial hardness is
within the above range, the preparation can be easily adhered to
gaps or curves of teeth.
[0054] The preparation may have the final hardness of 40,000 g or
less, preferably 30,000 g or less, measured at Compression mode of
Texture Analyzer (TA), at the time of removal.
[0055] The preparation having the final hardness within the above
range can achieve the desired effect (for example, effect of
improving sensitive teeth, tooth whitening effect, effect of
preventing gingivitis and the like) by smoothly releasing the drug,
and can have excellent shape fixing force.
[0056] In another embodiment of the present invention, the
preparation may have the initial compressibility of 0.1 gs to
30,000 gs, preferably in a range from 10 gs to 20,000 gs, measured
at Compression mode of Texture Analyzer (TA). When the
compressibility is within the above range, the preparation can be
easily adhered to gaps or curves of teeth.
[0057] The preparation may have the final compressibility of 50,000
gs or less, preferably 40,000 gs or less, measured at Compression
mode of Texture Analyzer (TA).
[0058] The preparation having the final compressibility within the
above range can achieve the desired effect (for example, effect of
improving sensitive teeth, tooth whitening effect, effect of
preventing gingivitis and the like) by smoothly releasing the drug,
and can have excellent shape fixing force. Such shape fixing force
can secure a sufficient contact time to the site where the drug is
required to reach, and therefore, it can be more advantageous in
achieving the desired effect.
[0059] The preparation according to one embodiment of the present
invention may have malleability, which can increase length of the
composition when pressing the preparation with a force of 0.5
kgf/cm.sup.2 or more, preferably 1 kgf/cm.sup.2 or more, at the
beginning of attachment. Specifically, the preparation may have
elongation percentage of 120% or more, preferably elongation
percentage of 150% or more when pressing the preparation with a
finger under conditions of standard relative humidity of 65% and
25.degree. C., or when pressing with a pressure roller with a force
of 0.5 kgf/cm.sup.2 or more, preferably a force of 1 kgf/cm.sup.2
or more. In another preferably embodiment, the preparation may have
the elongation percentage of 120% or more and 500% or less.
[0060] Further, the malleability of the preparation of the present
invention may be around 10% of the elongation percentage change
from the time of application of the preparation to the teeth or
tooth peripheries to the time of removal of the preparation. For
example, in one embodiment of the present invention, the oral
preparation of the preparation, wherein the first formulation
containing PVA (polyvinyl alcohol) and the second formulation
containing Borax are mixed, may have the same value of malleability
and elongation percentage. Namely, the malleability which is
measured at the time of application to the teeth surface, and the
elongation percentage which is measured at the time of removal when
the drug release has progressed by 60% or more after a certain
period of time according to the method for measuring elongation
percentage, i.e., a sample of a certain weight is made at size of 1
cm.sup.2 and the sample is pressed with a pressure roller at a
pressure of 2 kgf/cm.sup.2, are the same as 150% and 150%,
respectively.
[0061] The oral composition contained in the preparation of the
present invention may comprise a phase transition material, a phase
transition auxiliary material, an attachment-enhancing material of
the phase transition composition, and a material for helping drug
release.
[0062] The phase transition material is a substance which can cause
cohesive property to the oral composition. It may be carrageenan,
pectin, xyloglucan, gellan gum, ammonium alginate, magnesium
alginate, potassium alginate, sodium alginate, lithium alginate,
chitosan, poly-lactic acid (poly(D,L-lactic acid)),
polylactide-co-glycolide (poly(DL-lactide-co-glycolide)),
poly-caprolactone, polyacrylic acid (carbopol), polyvinylacetal
diethyl aminoacetate (AEA), hydroxypropylmethyl cellulose,
poly(methacrylic acid)-poly(ethylene glycol),
poly(D,L-lactide)-block-poly(ethylene
glycol)-block-poly(D,L-lactide), PEG-oligoglycolyl-acrylate,
poly(N-isopropyl acrylamide), sucrose acetate isobutyrate,
polyvinyl alcohol, polyvinyl acetate, glyceryl monooleate, glyceryl
monolinoleate, glyceryl monoarachidonate, glyceryl monostearate and
the like alone, or a combination of two or more thereof, and any
material that can be used as a phase transition material in the art
can be used, but not limited to the above examples.
[0063] The malleable oral composition may comprise the
attachment-enhancing material of the phase transition composition,
that is adhesive to teeth or has adhesiveness retention force; and
that is well compatible with the phase transition material. For
example, precipitated silica for thickening, colloidal silicone
dioxide, polyvinyl pyrrolidone, poly methyl vinyl ether and maleic
acid copolymers (gantrez), shellac, rosin, poloxamer, hyaluronic
acid, acrylate copolymer (Eudragit L-100, L-100,55), hydroxypropyl
methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), polyacrylic
acid, polyethylene glycol, ethyl cellulose or a mixture thereof,
but not limited thereto. Preferably, it may be hydroxypropyl methyl
cellulose (HPMC) or ethyl cellulose or a mixture thereof. Such
polymer can be used by dissolving thereof in water or a solvent
(for example, ethanol), but crosslinked polymers also can be used.
For example, the polymer may be crosslinked polyacrylic acid, or
crosslinked polyvinyl pyrrolidone, and such crosslinked polymer can
be used alone or in combination with a non-crosslinked polymer. In
the case of a polymer obtained by cross-linking polymers having
excellent adhesive force to teeth or gums, it is advantageous to
improve adhesion of the composition as well as to improve the
residuality because it is not dissolved in water or ethanol while
exhibiting adhesive force after absorbing water.
[0064] The phase transition auxiliary material is a substance that
can induce phase transition, control phase transition rate and
adjust a degree of phase transition, and a calcium ion can be used.
It is preferable that the calcium ion is water-soluble, but a
calcium ion, which is insoluble in neutral or alkaline condition
but can easily be converted into water-soluble in an acidic
condition, also can be used. For example, the phase transition
auxiliary material may be at least one selected from: a calcium ion
source of calcium carbonate, calcium phosphate dibasic
(CaHPO.sub.4), barium carbonate, zinc carbonate, calcium chloride,
calcium lactate, calcium citrate, calcium aspartate, calcium
saccharate, calcium oxovalerate, calcium gluconate, calcium
lactobionate and calcium lactogluconate; a chelating agent such as
barium carbonate, zinc carbonate, sodium bicarbonate, sodium
carbonate, tetraborate, tripolyphosphate, ethylenediamine
tetraacetic acid, tetrasodium pyrophosphate, sodium acid
pyrophosphate, Sporix (acidic sodium metaphosphate), trisodium
trimetaphosphate and the like; acetic acid, malic acid, lactic
acid, gluconic acid, ascorbic acid, boric acid or a mixture
thereof, or a salt thereof; and NaOH, KOH or a mixture thereof.
[0065] The phase transition material, the phase transition
auxiliary material and the attachment-enhancing material of the
phase transition material contained in the composition are
exemplarily listed, but not necessarily limited the above examples.
According to another embodiment of the present invention, depending
on the mechanism, the phase transition material, the phase
transition auxiliary material and the attachment-enhancing material
can be used indiscriminately. For example, if the phase transition
material is polyvinyl alcohol, the phase transition auxiliary
material may be tetraborate, and the material for enhancing
adhesive force may be alginate or colloidal silica. In another
embodiment, if the phase transition material is alginate, the phase
transition auxiliary material may be calcium, and the material for
enhancing adhesive force may be methyl vinyl ether and maleic acid
copolymer (gantrez).
[0066] The material for helping drug release may be any material
that can form a channel, a porous structure or bubble (foam) in the
formulation. For example, in the case that the preparation is
consisting of two formulations of the first formulation and the
second formulation, one formulation contains an acid and the other
contains a base, so that bubbles are formed in the formulation when
the two formulations meet to form a viscous malleable composition.
Namely, the first formulation contains acetic acid, lactic acid,
malic acid, gluconic acid, ascorbic acid and the like or a
water-soluble salt thereof, e.g., sodium citrate, and the second
formulation contains at least one base selected from the group
consisting of sodium hydroxide (NaOH), potassium hydroxide (KOH),
sodium bicarbonate (baking soda) and sodium carbonate. Preferably,
the acid may be acetic acid, and the base may be sodium carbonate,
and more preferably, those may be sodium citrate and sodium
bicarbonate, which are an acid and a base mainly used in a
toothpaste.
[0067] The active ingredient may include, for example, ingredients
that can improve oral symptoms, and for example, it may be an
ingredient for tooth whitening, an ingredient for preventing cavity
containing a fluoride ion source, an ingredient for inhibiting
tartar formation, an anti-inflammatory ingredient, an
anti-bacterial ingredient, other vitamins, mineral ingredients and
the like. Further, it may also include ingredients for improving
sensitive teeth and for relieving its symptoms, and the like. More
specifically, for example, it may include: at least one fluoride
ion source selected from the group consisting of sodium fluoride,
stannous fluoride, indium fluoride, amine fluoride and sodium
monofluorophosphate; a reminerlaization agent containing
hydroxyapatite; and an ingredient for tooth whitening selected from
hydrogen peroxide, carbamide peroxide, calcium peroxide, perborate,
percarbonate, peroxyacid, persulfate, calcium chloride, barium
chloride, magnesium chloride, lithium chloride, sodium chloride or
a mixture thereof. For enhancing whitening effect, a condensed
phosphate can be used together with peroxides. The condensed
phosphate, which can be used, may be at least one of tetrasodium
pyrophosphate (TSPP), sodium acid pyrophosphate (SAPP), sodium
tripolyphosphate (STP), sodium potassium pyrophosphate,
tetrapotassium pyrophosphate, acidic sodium metaphosphate and
acidic sodium polyphosphate, and it may be used together with
peroxides. Such condensed phosphate also can be used for removing
tartar or inhibiting tartar formation. Further, it can also
contribute to the improvement of whitening effect by removing the
metal which affects the stain formation of teeth as a chelating
agent. The active ingredient may include an anti-bacterial agent
including triclosan, chlorhexidine, alexidine, hexetidine,
sanguinarine, benzalkonium chloride, salicylanilide, domiphen
bromide, cetylpyridinium chloride (CPC), tetradecylpyridinium
chloride (TPC) or a mixture thereof; an anti-inflammatory agent
including aspirin, ketorolac, flurbiprofen, piroxicam, meclofenamic
acid or a mixture thereof; thiamine, riboflavin, nicotinic acid,
pantothenic acid, pyridoxine, biotin, folic acid, vitamin B12,
lipoic acid, ascorbic acid, vitamin A, vitamin D, vitamin E,
vitamin K or a mixture thereof; or a mixture thereof, but not
limited thereto. Further, the drug effective for preventing and
improving periodontal diseases may be titrated extract of Zea Mays
L. unsaponifiable fraction, Magnoliae Cortex, Myrrha, Rhatany,
Chamomile, policresulen, titrated extract of Centella Asiatica,
nutmeg extract, dexpanthenol, .beta.-sitosterol, acetyl salicylic
acid and the like alone, or a mixture thereof at a certain mixing
ratio. The ingredient for improving and relieving sensitive teeth
symptoms may be zinc chloride, potassium phosphate, potassium
diphosphate, calcium chloride, oxalic acid, potassium oxalate,
ferric oxalate, vitamin E and the like alone, or a combination of
two or more thereof.
[0068] According to one embodiment of the present invention, the
preparation may be one-formulation type, or two-formulation type
consisting of the first formulation and the second formulation, and
three or more formulations may be mixed as required.
[0069] The first formulation and the second formulation of the
two-formulation type preparation are mixed and applied to teeth or
tooth peripheries, and in order to apply the preparation to teeth
or tooth peripheries, the viscosity of the preparation measured
after mixing the first formulation and the second formulation may
be increased, compared to before mixing, it may have moldability
like dough after mixing, and may have malleability.
[0070] The two-formulation type preparation may contain the active
ingredient in the first formulation, the second formulation or both
of the first formulation and the second formulation.
[0071] The two-formulation type preparation may selectively contain
the phase transition material, the phase transition auxiliary
material and the attachment-enhancing material in the first
formulation, the second formulation or both of the first
formulation and the second formulation.
[0072] For example, the two-formulation type preparation may
contain magnesium alginate as a phase transition material in the
first formulation. The two-formulation type preparation may contain
calcium chloride as a material for helping hardening of the phase
transition material, and hydroxypropyl cellulose as a material for
helping attachment to teeth or tooth peripheries in the second
formulation. In this case, the active ingredient may be
appropriately contained in consideration of compatibility of the
polymers contained in the first formulation and the second
formulation, characteristics thereof and the like.
[0073] Physical properties such as hardness, compressibility and
the like of the preparation of the present invention may be
maintained the same from right after attachment to just before
removal, and depending on the purpose, the physical properties may
be maintained the same until the sufficient amount of drug is
released in the oral cavity, but at the time of removal, hardness
may be somewhat increased to fix the shape. The time of removal of
the preparation of the present invention may vary depending on
ingredients contained in the preparation, but it may mean at 30 min
after application to teeth or tooth peripheries.
[0074] In another embodiment, the time of removal after attachment
to teeth may be, for example, the time at which drug release rate
into the oral cavity becomes 60 wt % or more, preferably 65 wt % or
more, more preferably 70 wt % or more, based on the amount of the
drug contained in the preparation at the beginning.
[0075] The preparation may further comprise a backing layer as
required when it is attached to teeth or tooth peripheries. The
backing layer may include a water-insoluble polymer, generally used
in an oral film, and for example, polyethylene (PE), polypropylene
(PP), ethylene vinyl acetate (EVA), cellulose acetate phthalate,
shellac, polyvinyl acetate, ethyl cellulose, polymethyl
methacrylate, methacryloylethyl betain/methacrylate copolymer
(Yukaformer; Manufacturer: Mitsubishi), methacrylic acid copolymer
(Eudragit L 100, Eudragit L 12,5, Eudragit L 100-55, Eudragit L
30D-55), aminoalkyl methacrylate copolymer (Eudragit E 100,
Eudragit E 12,5, Eudragit RL 100, Eudragit RL 30D) and the like may
be used.
[0076] In one embodiment of the present invention, the preparation
can be easily removed at the time of removal after drug release by
tooth brushing, and the time of removal may be at the time after 30
min after attachment.
Advantageous Effects
[0077] The preparation of the present invention can give high
adhesive force to the desired site despite gaps between teeth or
curves of teeth.
[0078] The preparation is adhered well to gaps between teeth,
thereby having excellent drug delivery efficiency. Further, it is
possible to sufficiently secure the contact time between the drug
delivery site and the preparation of the present invention because
the preparation does not flow down or is not diluted with saliva
after attachment, and therefore, it is advantageous to achieve the
desired efficacy.
[0079] Further, the preparation can be used conveniently because it
does not flow down when applied to teeth.
BRIEF DESCRIPTION OF THE DRAWINGS
[0080] Other objects and aspects of the present invention will
become apparent from the following descriptions of the embodiments
with reference to the accompanying drawings in which:
[0081] The accompanying drawings illustrate a preferred embodiment
of the present invention and together with the foregoing
disclosure, serve to provide further understanding of the technical
spirit of the present invention, and thus, the present invention is
not construed as being limited to the drawing.
[0082] In the drawing, T refers to teeth, and 1 refers to the
conventional strip for attaching to teeth. 2 refers to an active
ingredient, and 10 refers to the oral preparation manufactured
according to one embodiment of the present invention.
[0083] FIG. 1 is a drawing showing (a) the conventional strip for
attaching to the oral cavity and (b) the preparation according to
one embodiment of the present invention. Unlike the conventional
strip wherein an active ingredient 2 and a strip 1 are in separate
layers, the preparation according to one embodiment of the present
invention can have the form that the drug is dispersed in the
preparation.
[0084] FIG. 2 is a drawing prefiguratively showing the process of
attaching the preparation of the present invention 10 to teeth T
and then removing the preparation from the teeth over time.
[0085] FIG. 3 is a drawing prefiguratively showing the process of
hardening the preparation according to one embodiment of the
present invention after applying and adhering the preparation to
teeth. As can be seen from FIG. 3, the preparation of the present
invention can reach gaps between teeth.
[0086] FIG. 4 is a drawing prefiguratively showing the process of
attaching the preparation 10 to teeth T and then removing the
preparation from the teeth over time according to another
embodiment of the present invention.
EXAMPLES
[0087] Hereinafter, the present invention will be described in more
detail through the following embodiments. However, the embodiments
according to the present invention may be modified in many
different forms, and the scope of the present invention shall not
be construed as being limited to the embodiments described below.
The embodiments of the present invention are provided for
illustration to help a full understanding of the present invention.
Unless stated otherwise, % used herein are understood to mean wt
%.
[0088] Preparation and Test of Oral Composition in a Hardening
Ointment-Phase
[0089] [Preparation of Oral Preparation]
[0090] Oral preparations of Examples and Comparative Examples
having the following composition were prepared or purchased.
[0091] Preparations of Examples 1 to 3 were manufactured according
to the following method. The powder preparation of Example was
mixed by using a powder mixer, the gel of Example was prepared by
mixing a polymer with a mechanical mixer at a constant rate without
aggregation. Further, Example 3 was prepared by mixing with a
mechanical mixer after adjusting temperature to 50.degree. C.
TABLE-US-00001 TABLE 1 Example 3 Example 2 (Gel type, which is
Phase Example 1 (Film coating (Dual paint type with applicator
transition type type with separate backing layer) (dual syringe +
mixing tip)) by saliva) First Alginate 12% First Alginate 3.8% GMO
48.0% formulation Calcium Sulfate 15% formulation Acetic Acid 2.5%
EC 8.0% (powder) Sodium Phosphate 2% (gel-like) Magnoliae Cortex
0.1% Hydrogen Peroxide 6% Diatomite to 100% (active ingredient)
(active ingredient) Second Gantrez 0.38% Water to 100% Ethanol
44.0% formulation Zinc Chloride 0.18% Second Alginate 3.8%
(liquid-like (active ingredient) formulation Calcium Carbonate 2.0%
viscosity) Water to 100% (gel-like) Sodium Carbonate 1.9% Backing
layer PE film Water to 100%
[0092] Comparative Examples 1 to 5 were prepared. Comparative
Example 1 used P&G SensiStop (containing active ingredient of
improving sensitive teeth) and Comparative Example 2 used
Parodontax (containing active ingredient of improving
gingivitis).
[0093] Comparative Example 3 used Alginate Gel prescription
(alginate water-soluble gel prescription, tooth whitening),
Comparative Example 4 used Poloxamer prescription as a Temperature
Sensitive Polymer (tooth whitening) and Comparative Example 5 used
dental impression material prescription (silicone dual-syringe
prescription).
TABLE-US-00002 TABLE 2 Comparative Example 5 Dental impression
material Comparative Example 2 (Selection VPS Putty) (Product name:
Formulation: Comparative Example 1 Parodontax .TM.) Comparative
Example 3 Comparative Example 4 Reactive silicone gel (P&G
SensiStop .TM.) Formulation: (Alginate Gel) (Poloxamer) (First
formulation, Formulation: Strip Toothpaste Formulation: Gel
Formulation: Liquid Second formulation) Water Myrrha tint Alginate
1.5% PluronicF127 20% Vinyl Polysiloxane Glycerin Rhatany tint
Hydrogen Peroxide 6% Carbamide Peroxide 16% Impression Material
Cellulose Gum Chamomile tint Water to 100% (H.sub.2O.sub.2 5.6%)
(First formulation, Dipotassium Oxalate Water to 100% Second
formulation) (active ingredient ) Carbomer Sodium Hydroxide Sodium
Benzoate Potassium Sorbate PE film
[0094] [Test for Comparing Viscosity, Solubility and Convenience of
Use Before Attachment or at the Beginning of Attachment and Just
Before Removal]
[0095] Test Method
[0096] 1. Viscosity comparison test (Test method: Viscosity was
measured by using Rotary Viscometer) [0097] Evaluation device:
Brookfield Viscometer, No. 6, or 7 spindle, 5 rpm to 20 rpm,
20.degree. C. (room temperature) [0098] Evaluation method:
Viscosity of Comparative Example and Example was measured by using
Brookfiled Viscometer.
[0099] As follows, i) viscosity at the first application, ii)
viscosity in adhesion, iii) and viscosity just before removal were
measured. But, in the case of the prescription consisting of the
first formulation and the second formulation, each viscosity
measured before mixing the first formulation and the second
formulation was referred to as the viscosity at the time of
manufacture, and in the case of consisting of only the first
formulation, the viscosity at the time of manufacture was referred
to the same as the viscosity before the first application.
[0100] i) Viscosity at the first application: in the case of
consisting of the first formulation and the second formulation, it
is the same as the viscosity right after mixing, and in the case of
consisting of only the first formulation, it is the same as the
viscosity at the time of manufacture.
[0101] ii) Viscosity in adhesion: in the case of consisting of the
first formulation and the second formulation, the viscosity is
increased from the moment of mixing, and the viscosity means the
viscosity in the state where shape transformation can occur even at
a small pressure. In this test, for example, in the case of a
preparation whose total use time is 10 min, the preparation was
adhered to the desired site at 5 min after application, and in the
case of a preparation whose total use time is 30 min, the
preparation was adhered to the desired site at 5 min to 10 min
after application. The viscosity at this time was measured as the
viscosity in adhesion.
[0102] iii) Viscosity just before removal or upon completion of
drug release (the time at which about 70% to 100% of drug is
released): it means the viscosity when no further viscosity
increase occurs.
[0103] For example, in the case of a prescription for tooth
whitening and maintaining the whitening effect, which consists of
the first formulation and the second formulation, and is attached
for 30 min, {circle around (1)} Viscosity at the time of
manufacture means each viscosity before mixing, {circle around (2)}
Viscosity at the first application means the viscosity just before
application to teeth (when consisting of the first formulation and
the second formulation, it means the viscosity right after mixing)
{circle around (3)} Viscosity in adhesion means the viscosity at 10
min after application to teeth, {circle around (4)} Viscosity just
before removal or upon completion of drug release means the
viscosity at 30 min after application to teeth.
[0104] 2. Drug release rate comparison test (Test method: after
releasing test, the concentration of an active ingredient in a
solution was quantified)
[0105] A) Manipulation
[0106] 0.9% Sodium chloride solution 500 mL is poured in a test
tube and a temperature of a test solution is maintained at
32.+-.0.5.degree. C. during drug release test. Example or
Comparative Example as a sample is fixed on the upper side of a
disk which can be used as a sinker without absorbing, interfering
or reacting so that a target attachment surface faces outward.
Then, the disk is placed in the test tube with the sample-attached
side facing up, and drug release time is calculated from this point
of time. The sample-attached disk is aligned parallel to the bottom
of the test tube and a paddle blade. Distance between the paddle
blade and the sample surface is set to 25.+-.2 mm, and revolutions
per min (rpm) is set to 25. At the time of sampling, 100 mL of
sample solution is collected at a fixed position (a position 1 cm
away from the wall of the test tube, between the top of the paddle
blade and the test liquid surface) 30 min after the start of the
test.
[0107] Drug analysis method: Depending on the drug or the content,
an appropriate analysis is selected. For example, peroxides are
analyzed by titration, metal salts are analyzed by ICP analysis,
and natural extracts are analyzed by HPLC.
[0108] 3. Solubility comparison test: In the present invention,
solubility is defined as shape retention force during artificial
saliva (0.9% NaCl aqueous solution) release test. Recorded through
comparative observation (Whether the shape is collapsed or
maintained, or the same thickness and height are maintained or
decreased in the USP drug release test was observed and
recorded)
[0109] {circle around (1)} Solubility at the time of manufacture:
in the case of consisting of the first formulation and the second
formulation, 1 g each was taken and loaded in the same manner as
the drug release test, and then solubility was observed.
[0110] {circle around (2)} In the case of consisting of the first
formulation and the second formulation, solubility at the first
application, in adhesion and just before removal was measured by
loading the drug in the same manner as the drug release test, and
observing shape transformation over time.
[0111] 4. Convenience of use comparison test (Whether wet type or
dry type): The characteristics of the formulation applied to the
target in the oral cavity cause the inconvenience to use because
the formulation is smeared to the hands while being applied.
Further, those cause the inconvenience to use because the
formulation is smeared to gums or hands while applying and standing
for a certain time and is smeared to the hand during removal. Wet
type is characterized in that it is smeared to the hands when
touched, and dry type is characterized in that it is not smeared
when touched by hands because it maintains its shape.
[0112] [Efficacy/Effect Comparison Test]
[0113] 1. Clinical Survey Related to Improvement of Sensitive Teeth
for Humans
[0114] 1) Test subject and instructions: Example 1 group and
Comparative Example 1 group were attached to the sensitive teeth
area for 10 min once a day and then removed.
[0115] 2) After 1 week use, the survey was conducted to 15
volunteers who felt sensitive teeth per each group using 3-point
Likert scale.
[0116] 3) Criteria
[0117] 1 point: Compared to before use, the sensitive teeth
symptoms were similar or worsened.
[0118] 2 point: Compared to before use, the sensitive teeth
symptoms were slightly relieved.
[0119] 3 point: Compared to before use, the sensitive teeth
symptoms were a lot relieved.
[0120] 2. Clinical Survey Related to Improvement of Gingivitis
Symptoms-Relief of Gum Pain for Humans
[0121] 1) Test subject and instructions: Example 2 group and
Comparative Example 2 group were attached to the gum pain area for
10 min once a day and then removed.
[0122] 2) After 1 week use, the survey was conducted to 15
volunteers who felt gum pain per each group using 3-point Likert
scale.
[0123] 3) Criteria
[0124] 1 point: Compared to before use, the gum pain symptoms were
similar or worsened.
[0125] 2 point: Compared to before use, the gum pain symptoms were
slightly relieved.
[0126] 3 point: Compared to before use, the gum pain symptoms were
a lot relieved.
[0127] 3. Evaluation of Whitening Effect by In Vitro Tooth
Whitening Evaluation Method Using Artificial Teeth
[0128] (1) Preparation and Coloring of Hydroxyapatite (HAP) Tablet
Sample
[0129] Artificial teeth were made by using hydroxyapatite, a
component that forms 96% or more of teeth. Namely, hydroxyapatite
powder was tableted with IR press or tablet machine and then
sintered at 1000.degree. C. According to Stookey method, a process
of impregnating a sample in TSB (trypticase soybroth) solution in
which tea, coffee, iron and mucin protein were dissolved and drying
thereof was repeated for 1 week to prepare a colored artificial
sample. The colored sample was washed lightly with running water
using a toothbrush to remove stains that could be easily dissolved
or easily removed by water, and then dried. The initial L
(lightness) value was measured with a chroma meter.
[0130] (2) In Vitro Tooth Whitening Evaluation Method Using Colored
Artificial Teeth
[0131] After attaching Example 3, Comparative Example 3 and
Comparative Example 4 to a colored artificial teeth, respectively,
the artificial teeth was allowed to stand for 30 min under
conditions of the oral cavity, i.e., 37.degree. C., 98% humidity.
The sample was washed with water after removing Example and
Comparative Example and then dried. Then, L value was measured. The
delta L value, which is the difference between the L values before
and after attachment, was calculated.
[0132] [Test for Comparing Viscosity and Solubility Before
Attachment or at the Beginning of Attachment and Just Before
Removal]
[0133] 1. Viscosity of Example and Comparative Example at Each
Stage
[0134] (At this time, viscosity at each stage may have an error
range of about +/-50 cPs.)
TABLE-US-00003 TABLE 3 Comparative Comparative Comparative Example
1 Example 2 Example 3 Example 3 Example 4 Example 5 At the time of
Second First formulation 1,150 cps 13,000 cps 400 cps First
formulation manufacture formulation (14,000 cps) (700,000 cps) (5
cps) Second Second formulation formulation (14,000 cps) (700,000
cps) First application 30,000 cps 20,000 cps 1200 cps 13,000 cps
400 cps 700,000 cps In adhesion 120,000 cps 50,000 cps 2500 cps*
13,000 cps 600 cps >2,000,000 cps Just before 180,000 cps
>50,000 cps >5000 cps* 13,000 cps 600 cps Not measurable
removal (Upon completion of drug release)
[0135] As listed in Table 3, it was confirmed that after the first
application of the preparation, the viscosity of the preparations
of Examples of the present invention was increased until adhesion
of the preparations.
[0136] 2. Drug Release Rate of Example and Comparative Example at
Each Stage
TABLE-US-00004 TABLE 4 Comparative Example 1 Example 3 Example 5
After 10 min from 50% 60% 5% attachment After 30 min from >70%
>80% <5% attachment
[0137] As can be seen from Table 4, when the total loaded amount of
drug is referred as 100, it can be found that 70% or more of the
drug was released at the time of removal of the preparation, which
was 30 min after attachment. However, in the case of Comparative
Example 5 corresponding to a dental impression material, it can be
found that increase of the viscosity over time is the same as the
preparation of the present invention showed, but drug release was
not smooth.
[0138] 3. Solubility/Shape Retention Force of Preparation of
Example and Comparative Example at Each Stage
TABLE-US-00005 TABLE 5 Comparative Comparative Comparative Example
1 Example 2 Example 3 Example 4 Example 5 Solubility at Second
formulation First formulation Dissolved Dissolved First formulation
the time of (Dissolved) (Dissolved) (Maintained shape 100%)
manufacture Second formulation Second formulation (Dissolved)
(Maintained shape 100%) Solubility Maintained shape Maintained
shape Dissolved Partly maintained Maintained shape (100%) at first
(100%) (>90%) shape (>50%) application Preparation Maintained
shape Maintained shape Dissolved Partly maintained Maintained shape
(100%) residue (100%) (>90%) shape (<50%) just before
removal
[0139] As can be seen from Table 5, it can be found that the
preparations of the present invention have excellent shape
retention force just before removal. Namely, from the above
results, it can be found that the preparations of the present
invention can be adhered to fit to gaps between teeth after
application, and its shape can be maintained just before
removal.
[0140] 4. Comparison of Convenience of Use of Example and
Comparative Example
TABLE-US-00006 TABLE 6 Comparative Comparative Comparative Example
1 Example 2 Example 1 Example 2 Example 4 Degree of smear Second
formulation First formulation Smeared Smeared Smeared at the time
of (Smeared: Wet type) (Smeared: Wet type) (Wet type) (Wet type)
(Wet type) manufacture Second formulation (Smeared: Wet type)
Degree of smear Almost not smeared Almost not smeared Smeared
Smeared Smeared at first (Like dry type) (Like dry type) (Wet type)
(Wet type) (Wet type) application Degree of smear Not smeared Not
smeared Smeared Smeared Smeared just before (Wet type) (Wet type)
(Wet type) removal
[0141] Table 6 shows the result of confirming convenience of use in
the course of applying the preparations of the present invention.
As can be seen from the above result, it was confirmed that the
preparations of the present invention can be used conveniently and
sanitarily because the drug was almost not smeared to the hands
when applied and adhered to teeth, and there is no unnecessary loss
of the drug. However, the preparations of Comparative Examples gave
loss of the drug or inconvenience because the drug was smeared to
the hands.
[0142] 5. Comparison of Efficacy of Example and Comparative
Example
TABLE-US-00007 TABLE 7 Comparative Comparative Example 1 Example 1
Example 2 Example 2 Survey score 2.7 1.5 for sensitive teeth
symptom Survey score 2.4 1.4 for gum pain
[0143] As can be seen from Table 7, it was confirmed that Example 1
had better effect of relieving sensitive teeth, compared to
Comparative Example 1, and it was confirmed that Example 2 had
better effect of relieving gum pain symptoms, compared to
Comparative Example 2.
[0144] These results suggest that the formulations of Examples of
the present invention have excellent degree of adhesion to teeth
and gaps between teeth, so that active ingredient s are effectively
delivered to the target site.
[0145] Further, because Comparative Examples 1 and 2 are
toothpaste-type and the holding time of the drug delivered at the
time of the first application (brushing) was not long, the active
ingredient gradually disappeared over time. However, in the case of
the preparation of Examples of the present invention providing the
time for stable penetration of the active ingredient for a certain
period of time, it was thought that loss rate of the active
ingredient was low.
TABLE-US-00008 TABLE 8 .DELTA.L(Use once) .DELTA.L(Use twice)
Example 3 16.54 .+-. 2.19 31.49 .+-. 3.05 Comparative Example 3
5.29 .+-. 1.54 9.89 .+-. 1.85 Comparative Example 4 7.82 .+-. 3.19
13.26 .+-. 1.99
[0146] As can be seen from Table 8, Example 3 showed better tooth
whitening effect, compared to Comparative Examples 3 and 4. It was
confirmed that in the case of Comparative Examples 3 and 4, which
are gel-type and liquid-type, respectively, the amount of the
active ingredient delivered to teeth was smaller than the loaded
amount, and the whitening effect was significantly low because the
amount that flows down or disappears without being fixed after
being applied to teeth was a lot.
[0147] Preparation and Test of Oral Preparation Having
Malleability
[0148] Additional oral preparations, including Examples and
Comparative Examples having the same composition as some of
Examples 1 to 3 and Comparative Examples, were prepared and the
following tests were conducted.
[0149] [Preparation of Oral Preparation]
TABLE-US-00009 TABLE 9 Example 3 Example 4 Example 1 Example 2 (Gel
type, which is (Compression band type, (Film coating type (Dual
paint type with applicator Phase transition type Example having
form like with separate backing layer) (dual syringe +mixing tip))
by saliva) plaster) First Alginate 12% First Alginate 3.8% First
formulation: First formulation (Liquid): formulation Calcium
Sulfate 15% formulation Acetic Acid 2.5% Gel-like PVA 3% (powder)
Sodium Phosphate 2% (gel-like) Magnoliae Cortex extract Second
formulation: Magnoliae Cortex extract Diatomite to 100% 0.1%
(active ingredient) GMO 48.0% 0.1% Water to 100% EC 8.0% Ethanol 1%
Hydrogen Peroxide 6% Water to 100% Second Gantrez 0.38% Second
Alginate 3.8% (active ingredient) Second formulation formulation
Zinc Chloride 0.18% formulation Calcium Carbonate 2.0% Ethanol
44.0% (Liquid): (liquid-like (active ingredient) (gel-like) Sodium
Carbonate 1.9% Borax 4% viscosity) Water to 100% Water to 100%
Backing PE film layer
[0150] Comparative Examples 1 to 3 and 5 were prepared as
follows.
TABLE-US-00010 TABLE 10 Comparative Example 5 Dental impression
material Comparative Example 2 (Selection VPS Putty) (Product name:
Reactive silicone gel Comparative Example 1 Parodontax .TM.)
Comparative Example 3 (Formulation: (P&G SensiStop .TM.)
Formulation: (Alginate Gel) First formulation, Formulation: Strip
Toothpaste Formulation: Gel Second formulation) Water Myrrha tint
Alginate 1.5% Vinyl Polysiloxane Glycerin Rhatany tint Hydrogen
Peroxide 6% Impression Material Cellulose Gum Chamomile tint Water
to 100% (First formulation, Dipotassium Oxalate Second formulation)
(active ingredient) Carbomer Sodium Hydroxide Sodium Benzoate
Potassium Sorbate PE film
[0151] Comparative Example 1 used P&G SensiStop (containing
active ingredient of improving sensitive teeth) and Comparative
Example 2 used Parodontax (containing active ingredient of
improving gingivitis). Comparative Example 3 used PVA Gel
prescription (Water-soluble gel prescription, improving
gingivitis/periodontitis) and Comparative Example 5 used dental
impression material prescription (silicone dual-syringe
prescription).
[0152] [Tests for Comparing Viscosity, Solubility and Convenience
of Use Before Attachment or at the Beginning of Attachment and Just
Before Removal]
[0153] Test Method
[0154] 1. Hardness Comparison Test (Test Method: Measured by Using
Texture Analyzer) [0155] Evaluation device: Stable Micro System TA
XT Plus [0156] Evaluation method: Hardness of Comparative Example
and Example was measured by using Texture Analyzer.
[0157] Hardness was measured at compression test mode of TA
(Texture Analyzer). After filling Example and Comparative Example
into a 50 mL beaker, a 20 mm diameter aluminum probe for hardness
measurement was set, and then hardness was measured with test speed
of 1.5 mm/s, distance as target mode and distance of 10 mm. The
hardness calculated from the device is the peak value of the first
cycle.
[0158] {circle around (1)} Hardness at the time of manufacture: In
the case of prescription consisting of the first formulation and
the second formulation, each hardness measured before mixing the
first formulation and the second formulation. In the case of
consisting of only the first formulation, the hardness at the time
of manufacture was referred to the same as the hardness before the
first application.
[0159] {circle around (2)} Hardness at the first application: In
the case of prescription consisting of the first formulation and
the second formulation, hardness right after mixing. In the case of
consisting of only the first formulation, the hardness was referred
to the same as the hardness at the time of manufacture.
[0160] {circle around (3)} Hardness in adhesion: In the case of
consisting of the first formulation and the second formulation,
hardness is increased from the moment of mixing, and the hardness
means the hardness in the state where shape transformation can
occur even at a small pressure (Hardness when adhered to the
desired site)
[0161] {circle around (4)} Hardness just before removal or upon
completion of drug release: Hardness when no further hardness
increase occurs. Hardness just before removal. Hardness when drug
release is completed.
[0162] For example, in the case of a prescription for treating and
preventing gingivitis, which consists of the first formulation and
the second formulation, and is attached for 30 min, {circle around
(1)} Hardness at the time of manufacture means each hardness before
mixing, {circle around (2)} Hardness at the first application means
the hardness just before application to teeth (when consisting of
the first formulation and the second formulation, it means the
hardness right after mixing) {circle around (3)} Hardness in
adhesion means the hardness at 10 min after application to teeth,
{circle around (4)} Hardness just before removal or upon completion
of drug release means the hardness at 30 min after application to
teeth.
[0163] 2. Compressibility Comparison Test (Test Method: Measured by
Using Texture Analyzer)
[0164] Evaluation device: Stable Micro System TA XT Plus
[0165] Evaluation method: compressibility of Comparative Example
and Example was measured by using Texture Analyzer.
[0166] Compressibility was measured at compression test mode of TA
(Texture Analyzer). After filling Example and Comparative Example
into a 50 mL beaker, a 20 mm diameter aluminum probe for
compressibility measurement was set, and then compressibility was
measured with test speed of 1.5 mm/s, distance as target mode and
distance of 10 mm. The compressibility calculated from the device
is the area value of the first cycle.
[0167] 3. Malleability Comparison Test (Test Method: Degree of
Stretch when Pressing with a Constant Force after Measuring the
Initial Length)
[0168] In the case of a sample transformable on a PET film, 1 g
each of the sample was made to have the same length and breadth (1
cm.sup.2), a PE film was placed thereon, and then a 1 cm.sup.2 grid
plate was to show the PE film below. Then, when pressing the sample
with a constant force (2 kgf/cm.sup.2), the degree of stretch in
length was measured using a 1 cm.sup.2 grid plate, and elongation
percentage was calculated by calculating the average degree of
elongation in all directions. The elongation percentage was
measured under a general laboratory condition, i.e., under a
condition of relative humidity of about 65%, 25.degree. C.
[0169] 4. Drug Release Rate Comparison Test (Test Method: After
Releasing Test, the Concentration of an Active Ingredient in a
Solution was Quantified)
[0170] A) Manipulation
[0171] 0.9% Sodium chloride solution 500 mL is poured in a test
tube and a temperature of a test solution is maintained at
32.+-.0.5.degree. C. during drug release test. Example or
Comparative Example as a sample is fixed on the upper side of a
disk which can be used as a sinker without absorbing, interfering
or reacting so that a target attachment surface faces outward.
Then, the disk is placed in the test tube with the sample-attached
side facing up, and drug release time is calculated from this point
of time. The sample-attached disk is aligned parallel to the bottom
of the test tube and a paddle blade. Distance between the paddle
blade and the sample surface is set to 25.+-.2 mm, and revolutions
per min (rpm) is set to 25. At the time of sampling, 100 mL of
sample solution is collected at a fixed position (a position 1 cm
away from the wall of the test tube, between the top of the paddle
blade and the test liquid surface) 30 min after the start of the
test.
[0172] B) Drug Analysis Method
[0173] Depending on the drug or the content, an appropriate
analysis is selected. For example, peroxides are analyzed by
titration, metal salts are analyzed by ICP analysis, and natural
extracts are analyzed by HPLC.
[0174] 5. Convenience of Use Comparison Test (Adhesive Force, Shape
Retention Force, Adhesive Force, Removability and the Like)
[0175] The characteristics of the formulation applied to the target
in the oral cavity cause the inconvenience to use because the
formulation is smeared to the hands while being applied. Further,
those cause the inconvenience to use because the formulation is
smeared to gums or hands while applying and standing for a certain
time and is smeared to the hand during removal. Wet type is
characterized in that it is smeared to the hands when touched, and
dry type is characterized in that it is not smeared when touched by
hands because it maintains its shape.
[0176] [Efficacy/Effect Comparison Test]
[0177] 1. Clinical Survey Related to Improvement of Sensitive Teeth
for Humans
[0178] 1) Test subject and instructions: Example 2 group and
Comparative Example 1 group were attached to the sensitive teeth
area for 10 min once a day and then removed.
[0179] 2) After 1 week use, the survey was conducted to 15
volunteers who felt sensitive teeth per each group using 3-point
Likert scale.
[0180] 3) Criteria
[0181] 1 point: Compared to before use, the sensitive teeth
symptoms were similar or worsened.
[0182] 2 point: Compared to before use, the sensitive teeth
symptoms were slightly relieved.
[0183] 3 point: Compared to before use, the sensitive teeth
symptoms were a lot relieved.
[0184] 2. Clinical Survey Related to Improvement of Gingivitis
Symptoms-Relief of Gum Pain for Humans
[0185] 1) Test subject and instructions: Examples 1 and groups and
Comparative Example 2 group were attached to the gum pain area for
10 min once a day and then removed.
[0186] 2) After 1 week use, the survey was conducted to 15
volunteers who felt gum pain per each group using 3-point Likert
scale.
[0187] 3) Criteria
[0188] 1 point: Compared to before use, the gum pain symptoms were
similar or worsened.
[0189] 2 point: Compared to before use, the gum pain symptoms were
slightly relieved.
[0190] 3 point: Compared to before use, the gum pain symptoms were
a lot relieved.
[0191] 3. Evaluation of Whitening Effect by In Vitro Tooth
Whitening Evaluation Method Using Artificial Teeth
[0192] (1) Preparation and Coloring of Hydroxyapatite (HAP) Tablet
Sample
[0193] Artificial teeth were made by using hydroxyapatite, a
component that forms 96% or more of teeth. Namely, hydroxyapatite
powder was tableted with IR press or tablet machine and then
sintered at 1000.degree. C. According to Stookey method, a process
of impregnating a sample in TSB (trypticase soybroth) solution in
which tea, coffee, iron and mucin protein were dissolved and drying
thereof was repeated for 1 week to prepare a colored artificial
sample. The colored sample was washed lightly with running water
using a toothbrush to remove stains that could be easily dissolved
or easily removed by water, and then dried. The initial L
(lightness) value was measured with a chroma meter.
[0194] (2) In Vitro Tooth Whitening Evaluation Method Using Colored
Artificial Teeth
[0195] After attaching Example 4 and Comparative Example 3 to a
colored artificial teeth, respectively, the artificial teeth was
allowed to stand for 30 min under conditions of the oral cavity,
i.e., 37.degree. C., 98% humidity. The sample was washed with water
after removing Example 4 and Comparative Example 3 and then dried.
Then, L value was measured. The delta L value, which is the
difference between the L values before and after attachment, was
calculated.
[0196] [Test for Comparing Hardness Before Attachment or at the
Beginning of Attachment and Just Before Removal]
[0197] 1. Hardness of Example and Comparative Example at Each
Stage
TABLE-US-00011 TABLE 11 Example Example Example Comparative
Comparative 4 1 2 Example 3 Example 5 At the Not Not Not Not First
time of measur- measur- measur- measurable formulation manu- able
able able 100 g facture Second formulation 100 g First 150 g 180 g
120 g Not 300 g appli- measurable cation In 150 g 5580 g 450 g Not
>33,600 g adhesion measurable Just before 150 g 12,000 g 600 g
Not >>Not removal measurable measurable (Upon com- pletion of
drug release)
[0198] As listed in Table 11, the oral preparations of Examples of
the present invention had the hardness in adhesion of around 5,000
g or less, and those have advantages that it can be transformed by
a small force due to low hardness, and therefore, when pressed
lightly with a finger at the beginning, it can be stretched to the
desired length, and the preparation has little feeling of foreign
body in gums or oral cavity because the preparation is soft. On the
contrary, in the case of Comparative Example 3, there is no
hardness, so it is equivalent to Examples in terms of softness.
However, it has disadvantages that it is difficult to maintain
shape after application because it is a general liquid gel, it is
scattered by pressing with a finger, it is inconvenient to use
because it is smeared to the hands and easily smeared to the
contact site to the gums, and it is easily washed out in the humid
oral cavity. In the case of Comparative Example 5, there is high
hardness. Thus, it has disadvantages that it may give a burden to
soft gums because it is impossible to transform shape if it is not
quickly adhered after application due to its hardness, and it is
impossible to release a drug after the hardness is increased.
[0199] 2. Compressibility of Example and Comparative Example at
Each Stage
TABLE-US-00012 TABLE 12 Example Example Example Comparative
Comparative 4 1 2 Example 3 Example 5 At the Not Not Not Not First
time of measur- measur- measur- measurable formulation manu- able
able able 100 gs facture Second formulation 100 gs First 700 gs 680
gs 650 gs Not 1200 gs appli- measurable cation In 700 gs 11,000 gs
1500 gs Not >55,000 gs adhesion measurable Just before 700 gs
16,000 gs 2000 gs Not >>Not removal measurable measurable
(Upon com- pletion of drug release)
[0200] As listed in Table 12, the oral preparations of Examples of
the present invention have low compressibility in adhesion, and it
means that those do not take much effort to make the desired
transformation for a certain period of time. Those have an
advantage that when pressed lightly with a finger, desired
deformations can be obtained, including not only size deformation
but also shape deformation, which makes it possible to easily fill
teeth gaps in many teeth simultaneously even if the teeth are
uneven. On the contrary, in the case of Comparative Example 3, it
has disadvantages that it is difficult to maintain shape after
application because it is a general liquid gel without hardness, it
is scattered by pressing with a finger, it is inconvenient to use
because it is smeared to the hands and easily smeared to the
contact site to the gums, and it is easily washed out in the humid
oral cavity. In the case of Comparative Example 5, compressibility
is sharply increased within several min after application and the
value is too high. Thus, it has disadvantages that it is hard to
use because it is impossible to transform shape if it is not
quickly adhered after application due to its hardness, and it is
difficult to release a drug.
[0201] 3. Comparison of Malleability of Example and Comparative
Example
TABLE-US-00013 TABLE 13 Comparative Comparative Example 4 Example 1
Example 3 Example 5 At first >300% >150% Not maintained 150%
application shape (Within 2 min) In adhesion >300% >150% Not
maintained Fixed (Within 10 shape min) Just before >300% 150%
Not maintained Fixed removal shape (after 30 min)
[0202] As can be seen from Table 13, the preparations of the
present invention could maintain the malleability just before
removal. By such malleability, the preparations of the present
invention could be completely adhered to gap between teeth, and
effectively deliver the drug to gaps between teeth and gums.
[0203] 4. Drug Release Rate of Example and Comparative Example
TABLE-US-00014 TABLE 14 Comparative Example 1 Example 2 Example 3
After 10 min from 50% 60% 5% attachment After 30 min from >70%
>80% <5% attachment
[0204] As can be seen from Table 14, in the case of Examples, it
can be confirmed that 70% or more of the drug was released at the
time of removal of the preparation, which was 30 min after
attachment, based on the loaded amount of the drug. However, in the
case of Comparative Example, it can be confirmed that removal of
the preparation increased the hardness and limited the drug
release.
[0205] 5. Comparison of Convenience of Use of Example and
Comparative Example
TABLE-US-00015 TABLE 15 Comparative Comparative Comparative Example
4 Example 1 Example 1 Example 2 Example 3 Degree of smear at First
formulation First formulation Smeared Smeared Smeared the time of
(Smeared: Wet type) (Smeared: Powder type) (Wet type) (Wet type)
(Wet type) manufacture Second formulation Second formulation
(Smeared: Wet type) (Smeared: Wet type) Degree of smear at Not
smeared Almost not smeared Smeared Smeared Smeared first
application (Dry type) (Like dry type) (Wet type) (Wet type) (Wet
type) Degree of smear just Not smeared Not smeared Smeared Smeared
Smeared before removal (Dry type) (Wet type) (Wet type) (Wet
type)
[0206] As cab be seen from Table 15, in the case of Comparative
Examples of the present invention, the drug was smeared to the
hands in the course of applying the preparations on the surface of
teeth, but Examples of the present invention could be conveniently
used because the drug was almost not smeared to the hands.
TABLE-US-00016 Comparative Comparative Example 4 Example 1 Example
1 Example 2 Survey score for -- 2.7 1.5 -- sensitive teeth Survey
score for gum pain 2.4 -- -- 1.4
[0207] As can be seen from Table 16, it was confirmed that Example
1 had better effect of relieving sensitive teeth, compared to
Comparative Example 1, and it was confirmed that Example 4 had
better effect of relieving gum pain symptoms, compared to
Comparative Example 2.
[0208] These results suggest that the formulations of Examples of
the present invention have excellent degree of adhesion to teeth
and gaps between teeth, so that active ingredient s are effectively
delivered to the target site.
[0209] Further, because Comparative Examples 1 and 2 are
toothpaste-type and the holding time of the drug delivered at the
time of the first application (brushing) was not long, the active
ingredient gradually disappeared over time. However, in the case of
the preparation of Examples of the present invention providing the
time for stable penetration of the active ingredient for a certain
period of time, it was thought that loss rate of the active
ingredient was low.
TABLE-US-00017 TABLE 17 .DELTA.L (Use once) .DELTA.L (Use twice)
Example 2 16.54 .+-. 2.19 31.49 .+-. 3.05 Comparative Example 3
5.29 .+-. 1.54 9.89 .+-. 1.85
[0210] As can be seen from Table 17, Example 2 showed better tooth
whitening effect, compared to Comparative Example 3. It was
confirmed that in the case of Comparative Example 3, which is
gel-type, the amount of the active ingredient delivered to teeth
was smaller than the loaded amount, and the whitening effect was
significantly low because the amount that flows down or disappears
by force without being fixed after being applied to teeth was a
lot.
INDUSTRIAL APPLICABILITY
[0211] The preparation of the present invention can be well adhered
to gaps between teeth well, and therefore, it can effectively
deliver a drug to teeth of gaps between teeth. The present
invention can provide a preparation attachable in the oral cavity,
which is convenient to use because it does not flow down when
applied to teeth.
[0212] The present invention has been described in detail. However,
it should be understood that the detailed description and specific
examples, while indicating preferred embodiments of the disclosure,
are given by way of illustration only, since various changes and
modifications within the scope of the disclosure will become
apparent to those skilled in the art from this detailed
description.
* * * * *